title: [Clonal eosinophilia revealed by recurrent Staphylococcus aureus infection].
abstract: Acquired eosinophilia is currently classified into secondary (reactional to underlying diseases), clonal (presence of a bone marrow histological, cytogenetic or molecular marker of a myeloid malignancy) and idiopathic (neither secondary nor clonal) categories. We report the case of a 47-year-old male who was admitted to the hospital for Staphylococcus aureus recurring infections. An hypereosinophilia was discovered and led to molecular analysis. The identification of FIP1L1-PDGFRA fusion gene permitted the diagnostic of clonal eosinophilia. Treatment by imatinib mesylate induced an haematological remission, the control of the infection and thoracotomy cicatrization. This case is original because of its infectious presentation and the efficacy of imatinib mesylate to control the infectious process.
authors.affiliation: Centre de réhabilitation cardio-respiratoire « La Maison du Mineur », Vence, France. f.vandenbos@maisondumineur.com
authors.forename: F
authors.initials: F
authors.lastname: Vandenbos
authors.forename: M
authors.initials: M
authors.lastname: Figueredo
authors.forename: M-C
authors.initials: MC
authors.lastname: Dumon-Gubeno
authors.forename: I
authors.initials: I
authors.lastname: Nicolle
authors.forename: A
authors.initials: A
authors.lastname: Tarhini
authors.forename: L-D
authors.initials: LD
authors.lastname: Medioni
authors.forename: H
authors.initials: H
authors.lastname: Naman
authors.forename: J
authors.initials: J
authors.lastname: Mouroux
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001549:Benzamides; D015415:Biomarkers / Q000378:metabolism; D002999:Clone Cells / Q000473:pathology; D004802:Eosinophilia / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics / Q000382:microbiology*; D015321:Gene Rearrangement; D006801:Humans; D000068877:Imatinib Mesylate; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D020796:Receptor, Platelet-Derived Growth Factor alpha / Q000235:genetics; D012008:Recurrence; D012307:Risk Factors; D012907:Smoking / Q000009:adverse effects; D013203:Staphylococcal Infections / Q000150:complications*; D013211:Staphylococcus aureus / Q000187:drug effects / Q000302:isolation & purification; D016896:Treatment Outcome; D039221:mRNA Cleavage and Polyadenylation Factors / Q000235:genetics
chemical_list: D000900:Anti-Bacterial Agents; D001549:Benzamides; D015415:Biomarkers; C479818:FIP1L1 protein, human; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D039221:mRNA Cleavage and Polyadenylation Factors; D000068877:Imatinib Mesylate; D020796:Receptor, Platelet-Derived Growth Factor alpha